Portfolio Lab

TherapeuticsMD, Inc.

  • Stock
  • Ticker TXMD
  • ISIN US88338N2062
  • Nasdaq

Health care · Pharmaceuticals · USA

$1.71 −5.52%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of TherapeuticsMD, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

TXMDGlobal equities (VT)

$10,000 grew to $49. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −99.8% in 03/2025, measured from the peak in 04/2017. The old peak has not been reached again yet.

1-year return
−10.9%
5-year return p.a.
−43.0%
10-year return p.a.
−41.2%
Volatility p.a.
71.6%
Largest decline
−99.8%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue0.70.41.00.80.90.70.91.3
Operating income-0.7-1.3-0.7-0.9-1.6-0.7-0.8-0.5
EBITDA-0.6-1.2-0.6-0.8-1.5-0.6-0.7-0.4
Net income0.3-0.70.60.2-0.60.10.20.5
Earnings per share0.02-0.060.050.01-0.050.010.010.04
Balance sheet
Total assets3938393938383838
Liabilities1111111111111010
Equity2727272727272728
Cash5.15.76.17.17.58.49.210
Cash flow
Operating cash flow0.00.70.41.00.40.90.81.3
Free cash flow0.00.70.41.00.40.90.81.3

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2025 at +89.5%, weakest 2021 at −70.6%. 2 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
13 Nov 2026$0.04
11 Aug 2026$0.01
12 May 2026$0.01
30 Mar 2026−$0.05
12 Nov 2025$0.01
12 Aug 2025$0.05
13 May 2025−$0.06
27 Mar 2025$0.02
12 Aug 2024−$0.09
29 Mar 2024−$0.07

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€18m
Market cap in trading currency
$19.8m
Enterprise value
$9.35m
P/E
171.0
P/S
5.28
P/B
0.72
EV/Sales
2.50
EV/EBITDA
–
Earnings yield
0.6%
FCF yield
17.0%

Results (last four quarters)

Revenue
$3.75m
Gross profit
–
EBITDA
−$3.19m
Net income
$122,000
Earnings per share
$0.01
Revenue per share
$0.32
Revenue growth
+60.6%
Earnings growth
+223.0%

Profitability

Gross margin
–
Operating margin
-95.3%
Net margin
3.3%
Return on equity
0.4%
Return on assets
0.3%

Balance sheet and cash flow

Cash
$10.4m
Cash per share
$0.90
Financial debt
–
Debt/equity %
–
Current ratio
3.32
Book value per share
$2.39
Operating cash flow
$3.37m
Free cash flow
$3.37m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
11.6m
Volume
25,043
Avg. volume 3 months
23,838
Relative volume
1.0

Price and technicals

Price
$1.71
1 day
−5.5%
52-week high
$2.77
52-week low
$1.46
Distance to 52-week high
−38.3%
Distance to 52-week low
+17.1%
Distance to 50-day line
−11.6%
Distance to 200-day line
−17.5%
RSI (14)
40
Volatility 1M
53.7%

Performance

1 week
−8.6%
1 month
−7.6%
3 months
−17.4%
6 months
−19.3%
YTD
+4.9%
1 year
+3.6%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has TXMD performed since 11/2016?

$10,000 grew to $49 by 20 Nov 2026, which is −41.2% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is TXMD?

Volatility was 71.6% per year, measured on monthly returns. The largest decline from a peak was −99.8%, with the low in 03/2025.

How does TXMD compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, TXMD returned −41.2% at 71.6%. The correlation of monthly returns was 0.28; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.